A5058082024- Advanced Proteomics Techniques and Applications
- Mass Spectrometry Techniques and Applications
- Ubiquitin and proteasome pathways
- Metabolomics and Mass Spectrometry Studies
- Protein Degradation and Inhibitors
- Bioinformatics and Genomic Networks
- Glycosylation and Glycoproteins Research
- Peptidase Inhibition and Analysis
- HER2/EGFR in Cancer Research
- Genomics and Phylogenetic Studies
- RNA and protein synthesis mechanisms
- RNA modifications and cancer
- Monoclonal and Polyclonal Antibodies Research
- Lung Cancer Treatments and Mutations
- Cytokine Signaling Pathways and Interactions
- Histone Deacetylase Inhibitors Research
- Gene expression and cancer classification
- Plant Molecular Biology Research
- Cancer, Hypoxia, and Metabolism
- PI3K/AKT/mTOR signaling in cancer
- Multiple Myeloma Research and Treatments
- Microtubule and mitosis dynamics
- RNA Research and Splicing
- Cancer-related gene regulation
- Computational Drug Discovery Methods
Technical University of Munich
2016-2025
Bioanalytica (Switzerland)
2012-2025
German Cancer Research Center
2016-2025
Deutschen Konsortium für Translationale Krebsforschung
2016-2025
Heidelberg University
2015-2024
Klinikum rechts der Isar
2024
Leibniz-Institute for Food Systems Biology at the Technical University of Munich
2011-2023
Bavarian State Research Center for Agriculture
2017-2022
German Marine Research Consortium
2022
University Hospital Heidelberg
2020
Mapping human drug targets in the cell To understand both beneficial and side effects of a drug, one would need to know its full binding profile all cellular proteins. Savitski et al. take significant steps toward meeting this daunting challenge. They monitored unfolding or “melting” over 7000 proteins measured how small-molecule changes individual melting profiles. As proof principle, 50 were identified for an inhibitor known bind broad spectrum kinases. Two cancer drugs, vemurafib...
Kinase inhibitors are important cancer therapeutics. Polypharmacology is commonly observed, requiring thorough target deconvolution to understand drug mechanism of action. Using chemical proteomics, we analyzed the spectrum 243 clinically evaluated kinase drugs. The data revealed previously unknown targets for established drugs, offered a perspective on "druggable" kinome, highlighted (non)kinase off-targets, and suggested potential therapeutic applications. Integration phosphoproteomic...
Article18 February 2019Open Access Transparent process A deep proteome and transcriptome abundance atlas of 29 healthy human tissues Dongxue Wang orcid.org/0000-0002-4402-0690 Chair Proteomics Bioanalytics, Technische Universität München, Freising, Germany Search for more papers by this author Basak Eraslan Computational Biology, Department Informatics, Technical University Munich, Garching bei Biochemistry, Quantitative Biosciences Gene Center, Ludwig Maximilian Universität, Thomas Wieland...
Calculating the number of confidently identified proteins and estimating false discovery rate (FDR) is a challenge when analyzing very large proteomic data sets such as entire human proteomes. Biological technical heterogeneity in experiments further add to there are strong differences opinion regarding conceptual validity protein FDR no consensus methodology for determination. There also limitations inherent widely used classic target–decoy strategy that particularly show lead...
Isobaric stable isotope labeling using, for example, tandem mass tags (TMTs) is increasingly being applied large-scale proteomic studies. Experiments focusing on proteoform analysis in drug time course or perturbation studies large patient cohorts greatly benefit from the reproducible quantification of single peptides across samples. However, such often require hundreds micrograms that cost reagents represents a major contribution to overall an experiment. Here, we describe and evaluate...